Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus Vaccines
Findings from National Institutes of Health, Department of Transfusion Medicine provide new insights into hepatitis C virus vaccines
December 17th, 2008
New investigation results, 'Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants,' are detailed in a study published in Vaccine. According to recent research published in the journal Vaccine, "Recent studies demonstrate that Th1-type immune responses against a broad spectrum of hepatitis C virus (HCV) gene products are crucial to the resolution of acute HCV infection. We investigated new vaccine approaches to augment the strength of HCV-specific Th1-type immune responses." "ELISPOT assay revealed that single or multiple protein immunization using both CpG ODN and...
Source: Vaccine Weekly (2008-12-17)
|
